Asia Pacific Adults Gain New Semaglutide Option
Abbott's Plosbrio® expands access to a once-weekly type 2 diabetes treatment across the region, pending local approvals.
Updated on Nov. 5, 2026 in Diabetes

Live Poll
Should prescription diabetes medicines be more widely available in your country?
Abbott will commercialise Plosbrio®, a second brand of semaglutide developed and manufactured by Novo, across Singapore and other Asia Pacific countries. The product is indicated as an adjunct to diet and exercise for adults with type 2 diabetes, and its availability will vary by market and depend on regulatory approvals.
Why it matters
The collaboration aims to expand access to evidence-based diabetes treatment in a region where the diabetes burden is growing rapidly. For people managing type 2 diabetes in Asia Pacific, it may broaden the range of available options, though local launch timing will differ by country.
The figures are drawn from manufacturer-reported exposure data across all semaglutide products and from regional diabetes prevalence estimates for Southeast Asia. Plosbrio® itself is described as a second brand of the same semaglutide molecule already marketed as Ozempic®, so the cited exposure reflects the drug rather than a new trial of this brand.
The players
Abbott
A global healthcare company active in diabetes care through its FreeStyle Libre® continuous glucose monitoring system, operating in more than 160 countries.
Novo Nordisk
A Danish pharmaceutical company and leader in diabetes care, developer of semaglutide and the Ozempic® and Plosbrio® brands.
World Health Organization
The United Nations agency that leads international public health and in 2025 added semaglutide to its essential medicines list.
The details
Semaglutide mimics human GLP-1, a hormone that helps regulate blood sugar, and the molecule shares about 94% homology with it. Plosbrio® will be delivered in the FlexTouch® pen, a once-weekly device offered in 0.25 mg, 0.5 mg, 1 mg and 2 mg strengths. Abbott will handle promotion and distribution across Asia Pacific, while Novo develops and manufactures the product.
Timeline
2019: Abbott and Novo began partnering to integrate FreeStyle Libre® CGM with Novo's connected insulin pens.
2025: The WHO added semaglutide to its essential medicines list.
November 5, 2026: Abbott and Novo announced the expanded Plosbrio® collaboration.
2050: The Southeast Asian adult diabetes population is projected to reach 185 million.
Health Landscape
Semaglutide's 2025 addition to the WHO essential medicines list marked its recognition as a core diabetes treatment worldwide. The Plosbrio® expansion extends that endorsement into regional commercial access across Asia Pacific, where diabetes prevalence is rising.
For adults with type 2 diabetes in Asia Pacific, this expansion may widen access to a once-weekly treatment option, but the product is available only as an adjunct to diet and exercise. Anyone considering a change in diabetes medication should discuss it with their physician first.
The takeaway
Expanded access to semaglutide across Asia Pacific reflects the growing regional diabetes burden. Anyone with type 2 diabetes who wants to know whether a semaglutide product fits their care plan should raise it with their doctor.
What happens next
Plosbrio® availability in each Asia Pacific market will depend on regulatory approvals and local launch planning, so timing is not yet set.
Further reading
For broader context on treatment options, explore our coverage of Diabetes.
Live Poll
Should prescription diabetes medicines be more widely available in your country?


